Business Responsibility and Sustainability Reporting for the financial year 2025-26.

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: August 25, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1 Dear Sir/Madam, Subject: Business Responsibility and Sustainability Report for the FY 2025-26 Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026. This is for your kind information and records. Thanking You, Yours Faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer ICSI Membership No.: A57415 Encl. As above Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 / Tel: +91- 022-20870033 Annual Report 2025-26 83 World Solara SSttaattuuttoorryy RReeppoorrttss Financial Statements Business Responsibility and Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1 Corporate Identity Number (CIN) of the Listed Entity L24230MH2017PLC291636 2 Name of the Listed Entity Solara Active Pharma Sciences Limited 3 Year of incorporation 2017 4 Registered office address ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai, Mumbai, Maharashtra, India, Pin code: 400703 5 Corporate address TICEL BIO PARK., 6th floor Module No. 601, 602, 603, Phase II - CSIR Road, Taramani, Chennai, Tamil Nadu, India, Pin code: 600113 6 E-mail investors@solara.co.in 7 Telephone +91 44 4344 6700 8 Website www.solara.co.in 9 Financial year for which reporting is being done April 1, 2025 to March 31, 2026 10 Name of the Stock Exchange(s) where shares are listed BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) 11 Paid-up Capital ₹ 44.51 Crores. 12 Name and contact details (telephone, email address) of the Ms. Pooja Jaya Kumar person who may be contacted in case of any queries on the BRSR Company Secretary report Ph: +91 44 43446700 / 080 46632102 Email: pooja.j@solara.co.in | Investors@solara.co.in 13 Reporting boundary - Are the disclosures under this report made Standalone. The boundary of reporting includes on a standalone basis (i.e., only for the entity) or on a consolidated Solara Active Pharma (the Company)’s following basis (i.e., for the entity and all the entities which form a part of its 10 locations: consolidated financial statements, taken together). y 06 manufacturing locations: − Ambernath − Cuddalore − Mangalore − Mysore − Pondicherry − Vizag* y 02 offices and 01 R&D Center: − Corporate Office, Chennai − Sales and Marketing office, Bangalore − R&D Center, Chennai y 01 registered office in Mumbai which is not considered as part of the reporting boundary due to its negligible operational footprint. 14 Name of assurance provider Not Applicable 15 Type of assurance obtained Not Applicable *Additionally, in the previous reporting year FY25, the Company recorded one month data in FY25 from Vizag plant as opposed to complete 12 months reporting in FY26. II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. Description of Main % of Turnover Description of Business Activity No. Activity of the entity 1 Active Pharmaceutical Design and manufacture commercial APIs across therapeutic categories, 100 % Ingredients complex products, including polymer-based APIs 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover) S. % of total Turnover Product/Service NIC Code No. contributed 1 Active Pharmaceutical Ingredients 21001 100% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 06 03 offices & 01 R&D Center* 10 International 0 0 0 *The 3 offices include a registered office in Mumbai which has not been considered as part of the reporting boundary since the environmental and social footprint is negligible relative to other locations. a. Markets served by the entity: a No. of Locations Locations Number National (No. of States) 21 International (No. of Countries) 64 b. What is the contribution of exports as a percentage of the total turnover of the entity? c. A brief type of customers Solara’s customers comprise leading generic and innovator pharmaceutical companies globally that utilize the Company’s Active Pharmaceutical Ingredients (APIs) in the manufacture of finished pharmaceutical formulations. IV. Employees 20. Details as at the end of Financial Year (FY2025-26) a. Employees and workers (including differently abled) Sl. Male Female Particulars Total (A) No. No. (B) % (B/A) No. (C) % (C/A) EMPLOYEES 1 Permanent (D) 1027 928 90% 99 10% 2 Other than Permanent (E) 5 4 80% 1 20% 3 Total employees (D + E) 1032 932 90% 100 10% WORKERS 4 Permanent (F) 642 642 100% 0 NA 5 Other than Permanent (G) 1434 1321 92% 113 8% 6 Total workers (F + G) 2076 1963 95% 113 5% b. Differently abled employees and workers: Sl. Male Female Particulars Total (A) No. No. (B) % (B/A) No. (C) % (C/A) DIFFERENTLY ABLED EMPLOYEES 1 Permanent (D) 1 1 100% 0 NA 2 Other than Permanent (E) 0 0 NA 0 NA 3 Total differently abled employees (D + E) 1 1 100% 0 NA DIFFERENTLY ABLED WORKERS 4 Permanent (F) 0 0 NA 0 NA 5 Other than Permanent (G) 0 0 NA 0 NA 6 Total differently abled workers (F+G) 0 0 NA 0 NA 21 Participation/Inclusion/Representation of women No. and percentage of Females (B) Representative Stakeholder Total (A) No (B) % (B / A) Board of Directors 8 1 13% Key Management Personnel 2 1 50% Note: Out of 4 Key Managerial Personnel, 2 Key Managerial Personnel are part of Board of Directors and have been considered under the same. 84 Solara Active Pharma Sciences Limited Annual Report 2025-26 85 World Solara SSttaattuuttoorryy RReeppoorrttss Financial Statements 22. Turnover rate for permanent employees and workers FY 2025-26 FY 2024-25 FY2023-24 (Turnover rate in current FY) (Turnover rate in previous FY) (Turnover rate in prior to previous FY) Male Female Total Male Female Total Male Female Total Permanent Employees 13% 10% 13% 31% 22% 30% 21% 28% 22% Permanent Workers 4% NA 4% 5% NA 5% 4% NA 4% V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. Names of holding / subsidiary / associate companies / joint ventures Indicate whether Does the entity indicated at Sr. Name of the holding /subsidiary / associate holding/ Subsidiary/ % of shares held column A, participate in the No. companies / joint ventures (A) Associate/ Joint by listed entity Business Responsibility initiatives Venture of the listed entity? (Yes/No) 1 Chemsynth Laboratories Private Limited Subsidiary 49% No 2 Shasun USA Inc Subsidiary 100% No 3 Synthix Global Pharma Solutions Limited Subsidiary 100% No Solara Active Pharma Sciences LTDA was also a 100% owned subsidiary as of FY 2024-25 which is no longer owned by the Company (effective 30th July 2025). VI. CSR Details Response 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) Yes (ii) Turnover (in `) 1,374.87 Cr. (iii) Net worth (in `) 1,252.88 Cr. VII. Transparency and Disclosures Compliances 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct FY2025-26 FY2024-25 Grievance Redressal Mechanism Stakeholder in Place (Yes/No) Number of Number of group from (If Yes, then provide the Number of complaints Remarks (e.g., Number of complaints who [Showing first 8,000 characters — download PDF for full document]